List of Excipients in Branded Drug NUEDEXTA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Avanir Pharmaceuticals Inc	NUEDEXTA	dextromethorphan hydrobromide and quinidine sulfate	64597-301	CELLULOSE, MICROCRYSTALLINE
Avanir Pharmaceuticals Inc	NUEDEXTA	dextromethorphan hydrobromide and quinidine sulfate	64597-301	CROSCARMELLOSE SODIUM
Avanir Pharmaceuticals Inc	NUEDEXTA	dextromethorphan hydrobromide and quinidine sulfate	64597-301	LACTOSE MONOHYDRATE
Avanir Pharmaceuticals Inc	NUEDEXTA	dextromethorphan hydrobromide and quinidine sulfate	64597-301	MAGNESIUM STEARATE
Avanir Pharmaceuticals Inc	NUEDEXTA	dextromethorphan hydrobromide and quinidine sulfate	64597-301	SILICON DIOXIDE

NUEDEXTA Excipient Strategy and Commercial Opportunities

Last updated: August 8, 2026

NUEDEXTA is an immediate-release oral capsule containing dextromethorphan hydrobromide and quinidine sulfate in a 20 mg/10 mg strength. Its commercial value comes from a differentiated fixed-dose combination, low-dose quinidine pharmacokinetic enhancement, and FDA approval for pseudobulbar affect rather than from a complex delivery system. The strongest excipient opportunities are lactose-free reformulation, improved swallowing, capsule-opening or sprinkle administration, moisture and stability control, and differentiated multiparticulate or orally disintegrating products.

Excipient innovation alone is unlikely to create a strong blocking position against an ANDA. Commercial protection would be stronger when the excipient system is linked to a measurable pharmacokinetic, stability, tolerability, or administration benefit and supported by formulation patents, clinical data, or a 505(b)(2) regulatory strategy.

What is NUEDEXTA and which excipients does the approved capsule use?

NUEDEXTA is marketed by Otsuka America Pharmaceutical following Otsuka Holdings' acquisition of Avanir Pharmaceuticals. The FDA approved NUEDEXTA in October 2010 for the treatment of pseudobulbar affect in patients with amyotrophic lateral sclerosis, multiple sclerosis, and other neurologic conditions. The product contains dextromethorphan hydrobromide and quinidine sulfate in a 20 mg/10 mg fixed-dose combination.[1]

The approved capsule uses conventional oral solid-dose excipients. The FDA prescribing information identifies the following inactive ingredients:

Component	Function in the dosage form
Lactose monohydrate	Diluent and capsule-fill carrier
Microcrystalline cellulose	Diluent and compression or granulation aid
Croscarmellose sodium	Disintegrant
Colloidal silicon dioxide	Glidant and flow-control agent
Magnesium stearate	Lubricant
Talc	Processing aid and anti-adherent
Capsule shell components	Gelatin, colorants and other shell materials

The formulation is conventional rather than modified-release. The central technical issue is delivering both active ingredients consistently while preserving quinidine's role as a CYP2D6 inhibitor. Quinidine increases systemic exposure to dextromethorphan, allowing the combination to achieve pharmacologic activity at the approved dose.[1]

What excipient strategy best fits NUEDEXTA?

The highest-value strategy is a platform approach that improves administration and tolerability without materially changing dextromethorphan or quinidine exposure.

Lactose-free reformulation

The marketed product uses lactose monohydrate. A lactose-free version could target patients with lactose intolerance, excipient avoidance preferences, or institutional formulary restrictions. Suitable substitutes include:

• Mannitol
• Isomalt
• Dibasic calcium phosphate
• Pregelatinized starch
• Spray-dried microcrystalline cellulose
• Co-processed cellulose-based fillers

Mannitol is commercially attractive for orally disintegrating and chewable formats because it provides a relatively clean mouthfeel. Dibasic calcium phosphate can improve powder density but may create compatibility, dissolution, or capsule-fill issues. Starch-based systems may provide lower cost but can introduce moisture-management and flow concerns.

A lactose-free hard capsule would have limited patent strength if it simply substitutes one diluent for another. The opportunity becomes more defensible if the replacement excipient is part of a validated system that improves content uniformity, dissolution, stability, or patient adherence.

Low-moisture and stability-focused formulation

Dextromethorphan and quinidine must remain chemically and physically stable through manufacturing, storage, and distribution. A low-moisture formulation could use:

• Anhydrous or low-water excipients
• Desiccant-enabled packaging
• High-barrier blister films
• Moisture-resistant capsule shells
• Controlled water activity during granulation and filling
• Antioxidant or chelating systems, if compatibility is demonstrated

A formulation patent would be stronger if it claimed a specific water-activity range, degradation threshold, impurity profile, dissolution limit, or stability period rather than a generic excipient substitution.

The commercial opportunity is greatest in markets with high humidity, where packaging and stability performance can affect distribution costs and product quality. A formulation that extends shelf life or permits less expensive packaging could create a supply-chain advantage even without a major clinical benefit.

Swallowing and dysphagia-oriented delivery

Pseudobulbar affect frequently occurs in patients with neurologic disease. Dysphagia, impaired dexterity, cognitive impairment, and dependence on caregivers are relevant product-design considerations. A capsule that requires conventional swallowing may create an adherence barrier.

Potential formats include:

• Orally disintegrating tablets
• Mini-tablets
• Sprinkle capsules
• Multiparticulate capsules
• Powder for administration on soft food
• Oral suspensions
• Ready-to-use liquid products

The principal technical constraint is dose uniformity. Quinidine is present at only 10 mg per unit dose, so a liquid, powder, or multiparticulate format must prevent segregation and ensure accurate delivery. The formulation must also demonstrate that administration with food or soft vehicles does not produce clinically meaningful changes in dextromethorphan or quinidine exposure.

A sprinkle product may offer the best balance between development complexity and market utility. It could preserve a unit-dose architecture while enabling administration to patients who cannot swallow a conventional capsule.

What excipient patents could protect a NUEDEXTA follow-on product?

Excipient patents are more defensible when they claim a complete pharmaceutical composition linked to a measurable technical result.

Potential claim categories include:

1. A lactose-free composition containing dextromethorphan and quinidine with defined dissolution and content-uniformity limits.
2. A low-moisture capsule with specified water activity and impurity control.
3. A multiparticulate formulation that prevents segregation of the 20 mg/10 mg active ratio.
4. A sprinkle formulation compatible with specified soft foods or liquids.
5. An orally disintegrating dosage form with rapid disintegration and controlled quinidine release.
6. A taste-masked liquid or powder formulation.
7. A formulation that maintains the approved dextromethorphan exposure range after administration with food.
8. A manufacturing process that improves blend uniformity at the low quinidine load.

The weakest claims would cover routine excipient lists without a demonstrated technical effect. The strongest claims would connect excipient selection to pharmacokinetic equivalence, stability, administration flexibility, or a specific patient population.

A follow-on sponsor should separate three layers of protection:

Protection layer	Commercial purpose
Composition patent	Protects the excipient and active-ingredient combination
Process patent	Protects blending, granulation, coating, filling or packaging
Method-of-use patent	Protects administration to patients with dysphagia or other defined needs

The method-of-use layer may be difficult if the clinical benefit is only improved convenience. The sponsor would need a credible clinical or adherence-related endpoint.

What FDA pathway applies to an excipient-based NUEDEXTA product?

A conventional generic that matches the reference product in active ingredients, strength, dosage form, route and performance would generally pursue an ANDA under section 505(j) of the Federal Food, Drug, and Cosmetic Act. A materially different dosage form or delivery system may require a 505(b)(2) application.

ANDA strategy

An ANDA sponsor would seek to establish bioequivalence to NUEDEXTA. Critical development issues include:

• Dextromethorphan and quinidine pharmacokinetics
• CYP2D6 inhibition and the exposure relationship between the two actives
• Food-effect performance
• Dissolution across physiologic pH conditions
• Content uniformity for low-dose quinidine
• Stability and impurity control
• Capsule or dosage-form comparability

A new excipient is not automatically barred, but FDA may require additional toxicology or justification, especially if the excipient has no established use in the proposed route and dose. FDA's Inactive Ingredient Database can support precedent analysis for excipient selection.[2]

505(b)(2) strategy

A 505(b)(2) application is more suitable for:

• An orally disintegrating tablet
• A liquid formulation
• A sprinkle product
• A modified-release dosage form
• A new administration route
• A product with a different dosing convenience or food-use profile

The sponsor could rely partly on FDA's prior findings for NUEDEXTA while submitting new data supporting the changed formulation. This pathway may provide greater differentiation but usually requires more clinical and regulatory work than an ANDA.

What is the Orange Book and patent status of NUEDEXTA?

NUEDEXTA is listed in FDA's Orange Book as an approved prescription drug product under NDA 021879.[3] The product is a small-molecule combination, so biosimilar competition does not apply. Competition would arise through ANDAs, 505(b)(2) products, authorized-generic activity, or branded reformulations.

NUEDEXTA's patent and exclusivity analysis should distinguish among:

• Active-ingredient combination patents
• Method-of-use patents
• Formulation patents
• FDA-granted regulatory exclusivity
• Orange Book-listed patents
• Patent litigation or Paragraph IV certifications

A Paragraph IV filing could challenge an Orange Book-listed patent before expiration. The commercial impact would depend on the specific patent claims, the applicant's non-infringement or invalidity position, litigation timing, and any settlement terms.

The principal risk for a formulation-focused entrant is that an ANDA may be blocked by active-combination or method-of-use patents even if the entrant uses a different excipient system. Conversely, a 505(b)(2) product with a novel dosage form may avoid some composition claims but remain exposed to method-of-use patents.

When does NUEDEXTA lose exclusivity and how could generic entry occur?

NUEDEXTA's regulatory and patent exclusivity should be analyzed separately. FDA approval in 2010 does not itself establish the final market-exclusivity date. The relevant dates depend on any applicable orphan-drug exclusivity, listed patents, pediatric exclusivity, patent-term adjustments, and litigation outcomes.[1][3]

Generic entry scenarios include:

Scenario	Likely commercial effect
First successful ANDA	Rapid price pressure and pharmacy substitution
Multiple ANDA approvals	Accelerated erosion of branded volume and net price
Authorized generic	Lower-price competition controlled by the innovator or licensee
505(b)(2) liquid or ODT	Differentiated competition with potentially higher pricing
Sprinkle formulation	Niche competition focused on dysphagia and caregiver use
Combination patent challenge	Potential early entry if the patent is invalidated or settlement permits launch

The largest risk is not necessarily full clinical replacement. Payers may move stable patients to the lowest-cost generic while preserving branded NUEDEXTA for patients who need specific dosage-form or support services.

Which companies could challenge or compete with NUEDEXTA?

Competition can come from four groups:

1. Generic drug manufacturers pursuing ANDAs.
2. Specialty pharmaceutical companies developing alternative dextromethorphan/quinidine dosage forms.
3. Companies developing dextromethorphan products for other neurologic or psychiatric indications.
4. Manufacturers offering compounded or institutionally prepared liquids, where legally permitted and clinically appropriate.

The main competitive asset is the fixed-dose combination. A competitor that uses dextromethorphan alone would not necessarily replicate the same exposure profile because quinidine provides pharmacokinetic inhibition of CYP2D6. A competitor would need to address dose optimization, drug interactions, QT-related safety considerations, and the established clinical role of the combination.[1]

What commercial opportunities exist for NUEDEXTA excipient innovation?

Premium differentiated products

A lactose-free or dysphagia-friendly product could support premium pricing if it secures formulary placement or reduces caregiver burden. The most credible target populations are patients with advanced neurologic disease, swallowing difficulty, feeding assistance, or institutional medication-administration constraints.

Licensing opportunities

Excipient and delivery-platform companies could license:

• Orally disintegrating technology
• Multiparticulate coating systems
• Taste-masking technology
• High-dose-uniformity powder systems
• Moisture-resistant capsule technology
• Unit-dose packaging
• Digital adherence or caregiver administration systems

A licensing deal would be more attractive if the technology has prior FDA use, scalable manufacturing, and demonstrated bioequivalence or clinical bridging data.

International expansion

Geographic opportunity is greatest where NUEDEXTA access is limited, local formulations are unavailable, or dysphagia-friendly dosage forms are underdeveloped. A regional partner could combine local regulatory expertise with a licensed formulation platform. Patent scope, data exclusivity, combination-product approval, and local requirements for excipient justification would need country-specific review.

Manufacturing and supply-chain advantage

A formulation that uses commonly available excipients, avoids specialized coating equipment, and tolerates standard high-barrier packaging could reduce cost of goods. Conversely, a novel excipient system may increase technical risk if it requires complex granulation, sterile processing, specialized encapsulation, or custom packaging.

How strong is the excipient opportunity compared with other NUEDEXTA strategies?

Strategy	Development complexity	Patent strength	Commercial potential
Lactose-free capsule	Low to moderate	Low	Moderate
Moisture-stable capsule	Moderate	Moderate if technically defined	Moderate
Sprinkle capsule	Moderate to high	Moderate to high	High in dysphagia population
Orally disintegrating tablet	High	Moderate	High if bioequivalence is established
Oral liquid	High	Moderate	Moderate to high
Modified release	High	High if clinically differentiated	Uncertain
New indication	High	Potentially high	High but clinically expensive
Simple excipient substitution	Low	Low	Low

The strongest near-term opportunity is a sprinkle or orally disintegrating formulation supported by bioequivalence, stability data, and claims directed to administration in patients with swallowing limitations. A simple lactose-to-mannitol substitution would be easier to develop but less defensible and more vulnerable to price competition.

Key Takeaways

• NUEDEXTA is a 20 mg/10 mg immediate-release dextromethorphan hydrobromide and quinidine sulfate capsule.
• The approved product uses conventional excipients, including lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, colloidal silicon dioxide, magnesium stearate and talc.
• Lactose-free reformulation is commercially feasible but has limited standalone patent value.
• Sprinkle, multiparticulate and orally disintegrating formats offer stronger differentiation for patients with dysphagia.
• Excipient patents should claim measurable stability, dissolution, content-uniformity, pharmacokinetic or administration benefits.
• An ANDA is appropriate for a substantially equivalent generic; a 505(b)(2) pathway is more suitable for materially different dosage forms.
• NUEDEXTA is a small-molecule product, so biosimilar risk does not apply.
• The principal commercial risks are Paragraph IV challenges, multiple generic entrants, price erosion and payer substitution.
• The best licensing targets are delivery platforms with prior FDA precedent and scalable manufacturing.
• A differentiated formulation must preserve the dextromethorphan exposure-enhancing role of low-dose quinidine.

FAQs

Can NUEDEXTA be reformulated without lactose?

Yes. Lactose can be replaced with mannitol, isomalt, dibasic calcium phosphate, starch or a co-processed cellulose system. The replacement must preserve blend uniformity, dissolution, stability and bioequivalence.

Would a NUEDEXTA orally disintegrating tablet require an ANDA?

Not necessarily. If the dosage form is materially different from the reference capsule, the sponsor may need a 505(b)(2) application rather than an ANDA.

Is quinidine an excipient in NUEDEXTA?

No. Quinidine sulfate is an active pharmaceutical ingredient. It is included at low dose to inhibit CYP2D6 and increase dextromethorphan exposure.

Could a liquid NUEDEXTA product obtain separate market protection?

Potentially. A liquid product could receive formulation or method-of-use protection if it has a patentable technical feature and obtains approval through an appropriate regulatory pathway.

Do biosimilars threaten NUEDEXTA?

No. NUEDEXTA contains small-molecule active ingredients. Competition would come from generics, 505(b)(2) products and branded reformulations rather than biosimilars.

References

1. U.S. Food and Drug Administration. (2023). NUEDEXTA prescribing information, NDA 021879.
2. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database.
3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
4. Otsuka Holdings Co., Ltd. (2024). Annual report.
5. U.S. Food and Drug Administration. (2024). Abbreviated new drug application and 505(b)(2) regulatory guidance.